Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Synaptic plasticity and learning in animal models of tuberous sclerosis complex.

Kirschstein T.

Neural Plast. 2012;2012:279834. doi: 10.1155/2012/279834. Epub 2012 Jul 15. Review.

2.

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O'Keefe RA, Bordey A.

Int J Dev Neurosci. 2013 Nov;31(7):667-78. doi: 10.1016/j.ijdevneu.2013.02.008. Epub 2013 Feb 26. Review.

3.

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.

Curatolo P.

Pediatr Neurol. 2015 Mar;52(3):281-9. doi: 10.1016/j.pediatrneurol.2014.10.028. Epub 2014 Nov 20. Review.

PMID:
25591831
4.

Impaired synaptic plasticity in a rat model of tuberous sclerosis.

von der Brelie C, Waltereit R, Zhang L, Beck H, Kirschstein T.

Eur J Neurosci. 2006 Feb;23(3):686-92.

PMID:
16487150
5.

Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.

Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M.

Hum Mol Genet. 2011 Feb 1;20(3):445-54. doi: 10.1093/hmg/ddq491. Epub 2010 Nov 9.

6.

Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis.

Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, Weller M.

J Neurochem. 2006 Jan;96(2):407-13. Epub 2005 Nov 21.

7.

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ.

Nat Med. 2008 Aug;14(8):843-8. doi: 10.1038/nm1788. Epub 2008 Jun 22.

8.

Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis.

Bateup HS, Johnson CA, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL.

Neuron. 2013 May 8;78(3):510-22. doi: 10.1016/j.neuron.2013.03.017.

9.

Deregulated mTOR-mediated translation in intellectual disability.

Troca-Marín JA, Alves-Sampaio A, Montesinos ML.

Prog Neurobiol. 2012 Feb;96(2):268-82. doi: 10.1016/j.pneurobio.2012.01.005. Epub 2012 Jan 25. Review.

PMID:
22285767
10.

The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.

Way SW, Rozas NS, Wu HC, McKenna J 3rd, Reith RM, Hashmi SS, Dash PK, Gambello MJ.

Hum Mol Genet. 2012 Jul 15;21(14):3226-36. doi: 10.1093/hmg/dds156. Epub 2012 Apr 24.

11.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
12.

Mechanism-based treatment in tuberous sclerosis complex.

Jülich K, Sahin M.

Pediatr Neurol. 2014 Apr;50(4):290-6. doi: 10.1016/j.pediatrneurol.2013.12.002. Epub 2013 Dec 5. Review.

13.

The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.

Nie D, Chen Z, Ebrahimi-Fakhari D, Di Nardo A, Julich K, Robson VK, Cheng YC, Woolf CJ, Heiman M, Sahin M.

J Neurosci. 2015 Jul 29;35(30):10762-72. doi: 10.1523/JNEUROSCI.4796-14.2015.

14.

[Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].

García-Peñas JJ, Carreras-Sááez I.

Rev Neurol. 2013 Feb 22;56 Suppl 1:S153-61. Spanish.

15.

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Wong M.

Epilepsia. 2010 Jan;51(1):27-36. doi: 10.1111/j.1528-1167.2009.02341.x. Epub 2009 Oct 8. Review.

16.

From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.

Ehninger D.

Neuropharmacology. 2013 May;68:97-105. doi: 10.1016/j.neuropharm.2012.05.015. Epub 2012 May 22. Review.

PMID:
22626986
17.

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

Kenerson H, Dundon TA, Yeung RS.

Pediatr Res. 2005 Jan;57(1):67-75. Epub 2004 Nov 19.

PMID:
15557109
18.

Evolving neurobiology of tuberous sclerosis complex.

Crino PB.

Acta Neuropathol. 2013 Mar;125(3):317-32. doi: 10.1007/s00401-013-1085-x. Epub 2013 Feb 6. Review.

PMID:
23386324
19.

Recent advances in neurobiology of Tuberous Sclerosis Complex.

Napolioni V, Moavero R, Curatolo P.

Brain Dev. 2009 Feb;31(2):104-13. doi: 10.1016/j.braindev.2008.09.013. Epub 2008 Nov 22. Review.

PMID:
19028034
20.

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.

Ehninger D, de Vries PJ, Silva AJ.

J Intellect Disabil Res. 2009 Oct;53(10):838-51. doi: 10.1111/j.1365-2788.2009.01208.x. Epub 2009 Aug 19. Review.

Supplemental Content

Support Center